<DOC>
	<DOCNO>NCT00003820</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody rituximab locate tumor cell either kill deliver tumor-killing substance without harm normal cell . PURPOSE : Phase II trial study effectiveness rituximab treat patient Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Rituximab Treating Patients With Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine partial complete response rate patient untreated recurrent/refractory lymphocyte predominant Hodgkin 's lymphoma treat rituximab . - Determine efficacy regimen term duration disease free survival time progression patient population . - Determine toxicity regimen patient . OUTLINE : Patients receive rituximab IV several hour week 4 week follow maintenance rituximab 6 , 12 , 18 month . PROJECTED ACCRUAL : A total 40 patient accrue study within approximately 18 month .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Patients must lymphocyte predominant Hodgkin 's disease Bcell lineage express CD 20 antigen . Patients eligible either untreated disease refractory/relapsed disease . Patients must &gt; = 3 year . Patients must performance status 02 . Patients must ANC &gt; 1500/ml platelet count &gt; 50,000/ml . A biopsy fine needle aspirate sample must show expression CD20 antigen L adnH cell . Patients must measurable disease ( least one tumor mass measure &gt; 1.0 cm large dimension ) . Patients must evidence active infection . Patients must read sign IRB approve informed consent . Adequate renal function indicate serum creatinine ( Cr ) &lt; 1.5X upper limit normal . Adequate liver function indicate alkaline phosphatase , bilirubin , AST , ALT &lt; 2X upper limit normal unless related primary disease . Patients high risk HBV infection screen prior enrollment . Concomitant recent treatment radiotherapy chemotherapy . Four week must pass radiotherapy cytotoxic therapy enroll ( six week nitrosourea compound ) . Major surgery , diagnostic surgery , within 4 week . Female patient must nonchildbearing potential use adequate contraception negative pregnancy test study entry . Serious nonmalignant disease ( e.g. , congestive heart failure , active uncontrolled bacterial , viral , fungal infection ) , condition , opinion investigator and/or sponsor , would compromise protocol objective . Treatment investigational drug within 30 day 5 halflives ( study drug long halflife ) prior entry study , whichever longer . Evidence active malignancy cure carcinomas situ cervix basal cell carcinoma skin . Life expectancy &lt; = 12 week . Concurrent treatment prednisone systemic steroid medication . Active HBV infection hepatitis .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>